162548-73-4

Basic information

• Product Name: 4,6-Difluoro-1-indanone
• Synonyms: 4,6-DIFLUORO-INDAN-1-ONE;4,6-DIFLUORO-1-INDANONE;4,6-DIFLUOROINDANE-1-ONE;6020 4,6-DIFLUORO INDAN-1-ONE;10037 4,6-DIFLUORO INDAN-1-ONE;4,6-Difluoro-2,3-dihydroinden-1-one;4,6-Difluoroindan-1-one 98%;10037 4,6-Difluoro indane-1-one
• CAS NO: 162548-73-4
• Molecular Formula: C9H6F2O
• Molecular Weight: 168.14
• Product Categories: Indanone & Indene
• Mol File: 162548-73-4.mol

Chemical Properties

• Boiling Point: 237.291 °C at 760 mmHg
• Flash Point: 89.925 °C
• Appearance: /
• Density: 1.362 g/cm³
• Vapor Pressure: 0.045mmHg at 25°C
• Refractive Index: 1.537
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4,6-Difluoro-1-indanone(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-Difluoro-1-indanone(162548-73-4)
• EPA Substance Registry System: 4,6-Difluoro-1-indanone(162548-73-4)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 162548-73-4(Hazardous Substances Data)

Usage

Uses

4,6-Difluoro-1-indanone is a useful research chemical.

Synthesis Reference(s)

Journal of Medicinal Chemistry, 46, p. 399, 2003 DOI: 10.1021/jm020067s

InChI:InChI=1/C9H6F2O/c10-5-3-7-6(8(11)4-5)1-2-9(7)12/h3-4H,1-2H2

Upstream product

• 162549-39-5 3-(2,4-difluorophenyl)propionyl chloride 
• 134672-70-1 3-(2,4-difluorophenyl)-propionic acid 

Downstream Products

• 32004-72-1 4,6-difluoro-2-methyl-indan-1-one 
• 1215279-80-3 (1aS,6aR)-3,5-difluoro-6,6a-di-hydro-1aH-1-oxa-cyclopropa[a]indene 
• 1279030-74-8 1-[1-((1R,2R)-4,6-difluoro-2-hydroxy-indan-1-yl)-3-(3-trifluoromethoxy-phenyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone 
• 173998-55-5 4,6-difluoroindan-1-ol 
• 1199782-88-1 (R)-4,6-difluoroindan-1-ylamine hydrochloride 

Relevant articles and documents

3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted-2H-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.

Indanylidenes. 1. Design and synthesis of (E)-2-(4,6-difluoro-1-indanylidene)acetamide, a potent, centrally acting muscle relaxant with antiinflammatory and analgesic activity

The design of rigid cyclic analogues derived from cinnamamide 1, (E)-N-cyclopropyl-3-(3-fluorophenyl)prop-2-enamide, and β-methylcinnamamide 2, (E)-N-cyclopropyl-3-(3-fluorophenyl)but-2-enamide, has led to the discovery of the potent, centrally acting muscle relaxant (E)-2-(4,6-difluoro-1-indanylidene)acetamide, 17. Compound 17 also possesses potent antiinflammatory and analgesic activity. This paper describes the synthesis and the muscle relaxant, antiinflammatory, and analgesic structure-activity relationships of 17 and 67 of its analogues. Compound 17 has been taken into phase I clinical trials.

Polyhalogen-substituted cinnamic acids and cinnamic acid derivatives and a process for the preparation of polyhalogen-substituted cinnamic acids and cinnamic acid derivatives

Polyhalogenated cinnamic acids and cinnamic acid derivatives are prepared by reacting diazonium salts accessible from polyhalogenated anilines with acrylic acid or acrylic acid derivatives in the presence of a homogeneous, palladium-containing catalyst at about ?5 to about +100° C. Some of the cinnamic acids and cinnamic acid derivatives obtainable in this way are new. Cinnamic acids and cinnamic acid derivatives which can be prepared according to the invention can be used for the preparation of indanones which are precursors for agro- and pharmaceutical chemicals and for substances having liquid-crystalline properties.

Bicyclic amide derivatives and their use as muscle relaxants

Novel compounds of formula (1) together with their salts and solvates have a number of uses in medicine, in particular as central muscle relaxants.

Bicyclic amide derivatives and their use as muscle relaxants

Novel compounds of formula (I) STR1 wherein R1, R2, R3 and R4 are each selected from hydrogen and fluoro and at least one and not more than two is fluoro; R5 is selected from hydrogen and C1 -C4 alkyl; R6 is selected from hydrogen, C1 -C4 ally and hydroxy; or R5 and R6 together with the ring carbon form a carbonyl group; R7 is selected from hydrogen and hydroxy, R8 and R9 are each selected from hydrogen, C1 -C4 alkyl and cyclo(C3 or C4) alkyl or together with the nitrogen form a morpholino group; and X is selected from a bond, methylene and --O-- and is always a bond or --O-- when any of R5, R6 and R7 is other than hydrogen and is always a bond when R5 and R6 together with the ring carbon form a carbonyl group; and their salts and solvates have a number of uses as central muscle relaxants. In particular, treatment of conditions associated with abnormally raised skeletal muscle tone. They are of special value in the relaxation of skeletal muscle in spastic, hypertonic and hyperkinetic conditions.